NICE backing for Takeda’s Adcetris for rare lymphoma
Standard of care in untreated systemic anaplastic large cell lymphoma (sALCL) has not changed in several decades
Read More
Tag: Adcetris
EU regulators approve Takeda’s Adcetris for sALCL
The decision brings a ‘much needed’ new treatment option to this patient community
Read More
Zytiga, Ajovy among latest SMC decisions
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Read More
Takeda’s Adcetris gets EU green light
Takeda has announced that the European Commission has extended the current marketing authorisation of Adcetris to include treatment of adults with previously untreated CD30+ Stage IV Hodgkin lymphoma.
Read More
NICE OKs three new therapies for blood cancer
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
Read More
US expands scope of Seattle Genetics’ Adcetris
US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Read More
EC OKs Adcetris for CD30-positive cutaneous T-cell lymphoma
The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy.
Read More
EU advisors back expanding use of Adcetris
Takeda’s Adcetris could soon be on the market in Europe as a second-line treatment for adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after regulatory advisors backed expanding the drug’s scope.
Read More
NICE u-turn backs Takeda’s Adcetris for sALCL
Takeda’s Adcetris has now been backed by the National Institute for Health and Care Excellence as an option to treat systemic anaplastic large cell lymphoma (sALCL), a very rare and aggressive cancer of the lymphatic system, on the NHS in England and Wales.
Read More
NHS future ‘uncertain’ for Adcetris in ALCL
Cost regulators for NHS treatments in England and Wales say they are currently minded not to recommend Takeda’s Adcetris on the NHS for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL), a cancer of the lymphatic system.
Read More
Final NICE nod for Takeda’s Adcetris in Hodgkin’s lymphoma
Certain patients with Hodgkin’s Lymphoma living in England and Wales can now expect routine access to Takeda’s Adcetris on the NHS after NICE deemed the drug a cost-effective use of resources in some scenarios.
Read More
NICE u-turn recommends some access to Takeda’s Adcetris
It is now looking likely that some patients with relapsed/refractory (R/R) Hodgkin lymphoma will be able to get routine access to Takeda’s Adcetris on the NHS after a major u-turn by cost regulators.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
